medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Number 2

<< Back Next >>

Rev Mex Neuroci 2019; 20 (2)

Clinical guideline: antiepileptic drugs of choice for focal and generalized seizures in adult patients with epilepsy

Rivera-Castaño L, Sentíes-Madrid H, Berumen-Jaik J, Martínez-Juárez IE

Language: English
References: 36
Page: 82-88
PDF size: 227.78 Kb.


ABSTRACT

The mainstay of treatment in patients with epilepsy is antiepileptic drugs (AEDs). Currently, there are a significant number of AEDs in Mexico. For the pharmacological management of the patient with epilepsy, it is important to know the pharmacokinetics, dosage, mechanism of action, and formulations of the AED. 70-80% of patients with either focal or generalized seizures are completely seizure free on AED monotherapy. When, despite the use of AED in monotherapy, seizure freedom is not achieved, a second AED should be used; AEDs with different mechanisms of action are empirically combined for this purpose. If a patient persists in having seizures with the use of an adequate AED, at appropriate doses and with therapeutic adherence, a correct diagnosis of the seizure type and a differential diagnosis should be reconsidered, using a new clinical evaluation and auxiliary diagnostic tests.


REFERENCES

  1. Patsalos PN. Antiepileptic Drug Interactions. A Clinical Guide. 3rd ed. London, UK: Springer; 2016.

  2. Genton P, Roger J. Antiepileptic drug monotherapy versus polytherapy: a historical perspective. Epilepsia. 1997;38(Suppl 5):S2-5.

  3. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279-86.

  4. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-8.

  5. Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014;55:1534-43.

  6. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-120.

  7. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512-21.

  8. Fisher RS, Cross JH, D’Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531-42.

  9. Freeman A, Concannon B, Cross H, et al. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clin Guidel. 2012;2012:1-177. Available from: http://www.nice.org.uk/cg137.

  10. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. Update ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial immunotherapy for epileptic seizures and syndromes. Epilepsies 2013; 54(3):551-563.

  11. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Mason AG. Antiepileptic drug immunotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Epilepsy Group 2017.

  12. Xiao Y, Gan L, Wang J, Luo M, Luo H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 2015.

  13. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2016;12:CD001904.

  14. Nolan SJ, Sudell M, Tudur Smith C, Marson AG. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2016;12:CD012065.

  15. Nolan SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2016;11:CD001031.

  16. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2017;2:CD001911.

  17. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database Syst Rev. 2016;4:CD001769.

  18. Nolan SJ, Muller M, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev. 2013; 5:CD003615.

  19. Campos MS, Ayres LR, Morelo MR, Carizio FA, Pereira LR. Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm. 2018;40:589-98.

  20. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000;22:75-80.

  21. Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia. 2009;50 Suppl 8:31-6.

  22. Thurman DJ, Begley CE, Carpio A, et al. The primary prevention of epilepsy: a report of the prevention task force of the international league against epilepsy. Epilepsia. 2018;59:905-14.

  23. Joshi R, Tripathi M, Gupta P, Gulati S, Gupta YK. Adverse effects and drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy. Indian J Med Res. 2017;145:317-26.

  24. Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol. 2010;23:157-63.

  25. Brodie MJ, Sills GJ. Combining antiepileptic drugs--rational polytherapy? Seizure. 2011;20:369-75.

  26. Kumari S, Mishra CB, Tiwari M. Polypharmacological drugs in the treatment of epilepsy: the comprehensive review of marketed and new emerging molecules. Curr Pharm Des. 2016;22:3212-25.

  27. Bonnett LJ, Tudur Smith C, Donegan S, Marson AG. Treatment outcome after failure of a first antiepileptic drug. Neurology. 2014;83:552-60.

  28. Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol. 2014;71:985-93.

  29. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010;51:7-26.

  30. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res. 1997;26: 423-32.

  31. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 1999;40:1141-6.

  32. Taing KD, O’Brien TJ, Williams DA, French CR. Anti-epileptic drug combination efficacy in an in vitro seizure model-phenytoin and valproate, lamotrigine and valproate. PLoS One. 2017;12:e0169974.

  33. Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2016;6:CD001909.

  34. Poolos NP, Castagna CE, Williams S, Miller AB, Story TJ. Association between antiepileptic drug dose and long-term response in patients with refractory epilepsy. Epilepsy Behav. 2017;69:59-68.

  35. Yasam VR, Jakki SL, Senthil V, et al. A pharmacological overview of lamotrigine for the treatment of epilepsy. Expert Rev Clin Pharmacol. 2016;9:1533-46.

  36. Lee BI, No SK, Yi SD, et al. Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy. Seizure. 2018;55:17-22.




2020     |     www.medigraphic.com